[A21-141] Nivolumab (malignant pleural mesothelioma) - Addendum to Commission A21-89

Last updated 16.12.2021

Project no.:
A21-141

Commission:
Commission awarded on 09.11.2021 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

First-line treatment of unresectable malignant pleural mesothelioma in adults

Result of dossier assessment:

Unchanged after addendum:

  • Patients with epithelioid tumour histology: added benefit not proven.
  • Patients with non-epithelioid tumour histology: indication of considerable added benefit.
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021-12-16 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form